Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Patients ≥ 3 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma will be
enrolled in this study. However, the primary objectives of this study are to 1) compare
overall survival, the time from randomization to death from any cause, for study subjects
3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma who receive
Antineoplaston therapy (Atengenal + Astugenal) + radiation therapy vs. radiation therapy
alone and 2) describe the toxicity profile (all subjects) for Antineoplaston therapy +
radiation therapy vs. radiation therapy alone.
A secondary objective is to compare progression-free survival for study subjects 3-21 years
of age with newly-diagnosed, diffuse, intrinsic pontine glioma treated with Antineoplaston
therapy + radiation therapy vs. radiation therapy alone.